دورية أكاديمية

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

التفاصيل البيبلوغرافية
العنوان: New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
المؤلفون: Senni, Michele, Paulus, Walter J, Gavazzi, Antonello, Fraser, Alan G, Díez, Javier, Solomon, Scott D, Smiseth, Otto A, Guazzi, Marco, Lam, Carolyn S. P, Maggioni, Aldo P, Tschöpe, Carsten, Metra, Marco, Hummel, Scott L, Edelmann, Frank, AMBROSIO, Giuseppe, Stewart Coats, Andrew J, Filippatos, Gerasimos S, Gheorghiade, Mihai, Anker, Stefan D, Levy, Daniel, Pfeffer, Marc A, Stough, Wendy Gattis, Pieske, Burkert M.
المساهمون: Senni, Michele, Paulus, Walter J, Gavazzi, Antonello, Fraser, Alan G, Díez, Javier, Solomon, Scott D, Smiseth, Otto A, Guazzi, Marco, Lam, Carolyn S. P, Maggioni, Aldo P, Tschöpe, Carsten, Metra, Marco, Hummel, Scott L, Edelmann, Frank, Ambrosio, Giuseppe, Stewart Coats, Andrew J, Filippatos, Gerasimos S, Gheorghiade, Mihai, Anker, Stefan D, Levy, Daniel, Pfeffer, Marc A, Stough, Wendy Gatti, Pieske, Burkert M.
سنة النشر: 2014
المجموعة: IRIS Università degli Studi di Perugia
مصطلحات موضوعية: Clinical trial, Diabetes mellitu, Exercise tolerance, Heart failure, Diastolic, Phenotype, Preserved ejection fraction, Aminobutyrate, Anemia, Angiotensin Receptor Antagonist, Angiotensin-Converting Enzyme Inhibitor, Arrhythmias, Cardiac, Cardiotonic Agent, Clinical Trials as Topic, Diabetic Angiopathie, Diuretic, Exercise Therapy, Homeostasi, Human, Hypertension, Pulmonary, Iron, Mineralocorticoid Receptor Antagonist, Molecular Targeted Therapy, Obesity, Observational Study as Topic, Patient Selection, Phosphodiesterase 5 Inhibitor, Sodium Channel Blocker
الوصف: The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist. There is no single explanation for the negative results of past HF-PEF trials. Potential contributors include an incomplete understanding of HF-PEF pathophysiology, the heterogeneity of the patient population, inadequate diagnostic criteria, recruitment of patients without true heart failure or at early stages of the syndrome, poor matching of therapeutic mechanisms and primary pathophysiological processes, suboptimal study designs, or inadequate statistical power. Many novel agents are in various stages of research and development for potential use in patients with HF-PEF. To maximize the likelihood of identifying effective therapeutics for HF-PEF, lessons learned from the past decade of research should be applied to the design, conduct, and interpretation of future trials. This paper represents a synthesis of a workshop held in Bergamo, Italy, and it examines new and emerging therapies in the context of specific, targeted HF-PEF phenotypes where positive clinical benefit may be detected in clinical trials. Specific considerations related to patient and endpoint selection for future clinical trials design are also discussed.
نوع الوثيقة: article in journal/newspaper
وصف الملف: STAMPA
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/25104786; info:eu-repo/semantics/altIdentifier/wos/WOS:000343736700009; volume:35; issue:40; firstpage:2797-815; lastpage:2815; journal:EUROPEAN HEART JOURNAL; http://hdl.handle.net/11391/1365545Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84920261725
DOI: 10.1093/eurheartj/ehu204
الإتاحة: https://doi.org/10.1093/eurheartj/ehu204Test
http://hdl.handle.net/11391/1365545Test
رقم الانضمام: edsbas.FF7DC6CD
قاعدة البيانات: BASE